Leukemia and Lymphoma

International Panel Updates Waldenström Macroglobulinemia Treatment Recommendations

February 27th 2021, 5:00pm


Updates on Waldenström macroglobulinemia treatment formed by an international consensus panel were recently finalized and published in The Lancet Haematology.

5 Leading Research Institutions to Target Toughest Cancers With New Public Foundation

February 25th 2021, 7:46pm


Break Through Cancer, a collaborative research effort between 5 top US academic cancer centers, aims to pursue solutions to some of the most difficult challenges in cancer research.

Study Explores Costs Linked With Adverse Events in Mantle Cell Lymphoma

February 18th 2021, 8:00pm


Hypertension, anemia, and infection were the most common adverse events associated with mantle cell lymphoma (MCL), while hepatotoxicity, stroke, and renal failure were the costliest per patient.

Interview: Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Cel

February 16th 2021, 8:00pm


Tanya Siddiqi, MD, director of the chronic lymphocytic leukemia program at Toni Stephenson Lymphoma Center provides insights on what the arrival of liso-cel could mean in the treatment landscape.

Azacitidine Is Shown to Improve Overall, Relapse-Free Survival in Older Adults With AML

February 15th 2021, 7:53pm


Older adults with acute myeloid leukemia (AML) saw increased overall and relapse-free survival, as well as preserved quality of life, following oral administration of 300-mg azacitidine.

FDA Updates Ibrutinib Label With 5-Year Data in Waldenström Macroglobulinemia

February 15th 2021, 7:45pm


The newly approved expanded label includes data from the final analysis of the phase 3 iNNOVATE study of ibrutinib plus rituximab vs rituximab alone.

Scientists Use CRISPR To Create Model of AML Progression

February 14th 2021, 12:15am


Using CRISPR, researchers were able to repeat the step-by-step conversion of a normal cell into a malignant one in acute myeloid leukemia (AML).

MCL Survival Likely Affected by Reason for Acalabrutinib Discontinuation

February 12th 2021, 3:56pm


Patients with mantle cell lymphoma (MCL) who discontinue acalabrutinib may have different outcomes depending on why they stopped and their eligibility for other therapies.

TKI Discontinuation Found to Benefit PROs in CML, Study Says

February 6th 2021, 4:30pm


Results from a new clinical trial suggest that discontinuation of tyrosine kinase inhibitors (TKIs) is safe, feasible and is associated with improvements in patient-related outcomes (PROs) in chronic myeloid leukemia (CML).

FDA Approves Less Toxic Liso-Cel in R/R Large B-Cell Lymphoma

February 5th 2021, 9:30pm


A CAR T-cell therapy that promises fewer side effects, and possibly lower hospital costs, wins approval after lengthy delays.